期刊文献+

高危型人乳头状瘤病毒感染在宫颈病变进展中的风险研究 被引量:25

Risk evaluation of high-risk human papillomavirus genotyping in cervical lesions progress
原文传递
导出
摘要 目的 探讨高危人乳头状瘤病毒(Human papillomavirus,HPV)基因分型检测在宫颈癌前病变诊断中的临床应用价值.方法 选取2012年12月至2015年3月在浙江省台州医院妇科初诊的4 095例宫颈癌筛查结果为HPV阳性者作为研究对象,分析HPV型别流行病学特征及HPV阳性者的宫颈组织病理学诊断结果;Logistic回归分析高危型HPV在宫颈癌前病变进展中的风险值.结果 浙江省台州地区女性宫颈HPV感染率从高到低依次为HPV52、16、58、39和56;宫颈上皮内瘤变(Cervical intraepithlial neoplasm,CIN)女性中HPV感染率从高到低依次为HPV16、52、58、33和31.Logistic回归分析显示HPV16、33感染者致CIN2+风险性较大,回归系数OR分别为3.670(95% CI:2.399 -5.612,P〈0.05)、2.045 (95%CI:1.087 -3.848,P〈0.05).CIN2+女性中,细胞学结果为NILM:Logistic回归分析结果显示HPV16感染者致CIN2+的风险较大,回归系数OR=2.539(95%CI:1.622 -3.976,P=0.000);细胞学结果为意义未明的非典型鳞状细胞(Atipical squamous cells of unknown significance,ASCUS):Logistic回归分析结果显示HPV16、58感染者发生CIN2+的风险较大,回归系数OR分别为1.911 (95% CI:0.530 -6.893)、1.757(95%CI:0.557 -5.548).结论 高危HPV基因分型检测在宫颈癌前病变诊断中具有重要的临床应用价值,尤其是对宫颈细胞学阴性、ASCUS患者临床处理时的重要参考指标,更精确宫颈癌筛查风险分层. Objective To evaluate the clinical value of high-risk humam papillomavirus (HR-HPV) genotyping in diagnosis of cervical lesions.Methods Between December 2012 and March 2015,a total of 4 095 women who were diagnosed as cervical inflammation-related disease were chosen to be evaluated in gynecological clinic at Taizhou Hospital of Zhejiang Province.All the women experienced HPV genotyping,analysis of the epidemiological characteristics of HPV types in Taizhou area and theresult of histopathologic diagnosis of HPV positive women.Logistic regression analysis was used to estimate the risk of HR-HPV gcnotyping in cervical lesion progression.Results Overall,HPV52 was the most prevalent genotype,followed by HPV16,58,39 and 56.Among the women with cervical intraepithelial neoplasm (CIN),HPV16 was the most frequent type,followed by HPV52,58,33 and 31.Logistic regression analysis showed that a higher risk of CIN2 + for women infected with HPV16 or HPV33,the regression coefficients OR were 3.670(95% CI:2.399-5.612,P 〈 0.05) and 2.045 (95% CI:1.087-3.848,P 〈 0.05),respectively.Logistic regression analysis showed that a higher risk of CIN2 + for NILM with positive HPV16,and the regression coefficients OR were 2.539(95% CI:1.622-3.976,P =0.000);the ASCUS with positive HPV16 and 58 had higher risk of CIN2 +,the regression coefficients OR were 1.911 (95% CI:0.530-6.893) and 1.757 (95% CI:0.557-5.548),respectively.Conclusions HPV genotyping has important clinical value to detect precancerous cervical lesions,especially when cervical cytology is negative,in management of patiemts with atypical squamous cells of an undertermined significance (ASCUS) or low grade squamous intraepithelial lesion(LSIL).
作者 许惠惠 朱海燕 章彤彤 尚贤文 俞加正 颜卫华 Xu Huihui Zhu Haiyan Zhang Tongtong Shang Xianwen Yu Jiazheng Yan Weihua(Medical Research Center Clinical Laboratory Health Management Center Department of Gynecology , Wenzhou Medical University Affiliated to Taizhou Hospital of Zhejiang Province, Linhai 317000, China)
出处 《中华实验和临床病毒学杂志》 CAS CSCD 2017年第4期302-306,共5页 Chinese Journal of Experimental and Clinical Virology
基金 浙江省公益技术应用研究计划项目(2016C33231) 浙江省医药卫生科技计划项目(2015KYB438) 台州市医学会科学研究基金(TZSYXH15-11)
关键词 乳头状瘤病毒 基因型 筛查 癌前状态 Human Papillomavirus Genotype Screening Precancerous Conditions
  • 相关文献

参考文献1

二级参考文献13

  • 1International Agency for Research on Cancer. GLOBOCAN 2012 : estimated cancer incidence, mortality and prevalence worldwide in 2012. Lyon, France: International Agency for Research on Cancer/World Health Organization, 2012.
  • 2Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol, 2012, 137:516-542. doi: 10. 1309/ AJCPTGD94EVRSJCG.
  • 3Xu HH, Shi WW, Lin A, et al. HLA-G 3" untranslated region polymorphisms influence the susceptibility for human papillomavirus infection. Tissue Antigens, 2014, 84:216-222. doi: 10. llll/tan. 12359.
  • 4De Sanjose S, Quint WG, Alemany L. Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cross-sectional worldwide study. cervical cancer: a retrospective Lancet Oncol, 2010, 11 : 1048-1066. doi: 10. 1016/S1470-2045(10)70230-8.
  • 5Kjaer SK, Frederiksen K, Munk C, et al. Long-term absolute risk of cervical intraepithelial neoplasia grMe 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst, 20|0, 102:1478-1d88. doi: 10. 1093/jnci/djq356.
  • 6Castle PE, Stoler MH, Wright TC, et al. Performance of carcinogenic human papillomavirus (HPV) testing and HPVI6 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol, 2011, 12: 880-890. doi: 10. 1016/S1470-2045 ( ll ) 70188-7.
  • 7De Sanjose S, Quint WG, Alemany L, et al. Hunrn papitlomavius genotype attribution in invasive cervical cancer: a retrospeetive cross-sectional worldwide study. Lancet Oncol, 2010,11: 1048- 1056. doi : 10. 1016/$1470-2045 ( 10)70230-8.
  • 8Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concmTent testing for human papillomavirus and cervical cytology : a population-based study in routine clinical practice. Lancet Oneol, 201 !, 12 : 663-672. doi: 10. 1016/S1470-2045 ( 11 )70145-0.
  • 9Ronco G, Giorgi-Rossi P, Carozzi F, et al; New Technologies for Cervical Cancer Screening (NTCC) Working Group. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepitheli neoplasia: a randomised controlled trial. Lancet Oncol, 2010, 11 : 249-257. doi: 10. 1016/S1470-2045 (09) 70360-2.
  • 10Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol, 2009, 10: 672-682. doi: 10. 1016/S1470-2045 (09) 70156-1.

共引文献26

同被引文献218

引证文献25

二级引证文献179

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部